Protea Biosciences Group, Inc. 4

Accession 0001144204-14-008800

CIK 0001335103operating

View on SEC.gov Company Profile

Filed

Feb 12, 7:00 PM ET

Accepted

Feb 13, 8:30 PM ET

Size

23.0 KB

Accession

0001144204-14-008800

Insider Transaction Report

Form 4

Period: 2011-09-30

Protea Biosciences Group, Inc.NONE

HARRIS LEONARD P

Director

Transactions

Purchase
Common Stock
2011-09-30$250001.00/sh+166,667$41,666,916,667→ 1,773,657 total
Purchase
Common Stock
2013-07-23$193667.00/sh+387,334$75,013,813,778→ 2,160,991 total
Award
Stock Option
2006-06-07$80000.00/sh+100,000$8,000,000,000→ 678,334 total
Exercise: $0.80From: 2006-06-07Exp: 2016-06-07→ Common Stock (100,000 underlying)
Award
Stock Option
2010-09-17$150000.00/sh+100,000$15,000,000,000→ 778,334 total
Exercise: $1.50From: 2010-09-01Exp: 2017-09-01→ Common Stock (100,000 underlying)
Purchase
Warrant
2010-10-18$200000.00/sh+100,000$20,000,000,000→ 878,334 total
Exercise: $2.00From: 2010-10-18Exp: 2015-10-18→ Common Stock (100,000 underlying)
Purchase
Warrant
2011-09-30+83,333→ 961,667 total
Exercise: $2.00From: 2011-09-30Exp: 2016-09-30→ Common Stock (83,333 underlying)
Award
Stock Option
2013-03-22$120313.00/sh+218,750$26,318,468,750→ 1,180,417 total
Exercise: $0.55From: 2013-03-22Exp: 2023-03-22→ Common Stock (218,750 underlying)
Conversion
Convertible Note
2013-07-23$193667.00/sh−387,334$75,013,813,778→ 1,047,083 total
Exercise: $0.50From: 2013-07-23Exp: 2013-07-23→ Common Stock
Purchase
Warrant
2013-07-23$319551.00/sh+290,501$92,829,885,051→ 1,337,584 total
Exercise: $1.10From: 2018-07-23Exp: 2018-07-23→ Common Stock (290,501 underlying)

Footnotes (5)

[F1]On September 30, 2011, Leo Harris (the "Reporting Person") acquired 166,667 shares of common stock and warrants to purchase 83,333 shares of common stock for an aggregate purchase price of $25,000.
[F2]On June 30, 2013, pursuant to the terms and conditions of a Conversion Agreement, dated June 18, 2013 (the "Conversion Agreement") the Reporting Person converted the Notes (as defined below) into 387,334 shares of common stock, in connection with the conversion of convertible promissory notes (each a "Note" and collectively, the "Notes") issued to the Reporting Person in an aggregate amount equal to $193,667.14 including principal and interest.The Notes accrue simple interest at the rate of 10% per annum and were initially convertible into shares of common stock at a conversion rate of $2.00 per share at any time prior to payment in full of the principal and interest due under the Notes. On March 22, 2013, the board of directors of the Company agreed to reduce the conversion rate of the Notes to $0.50 per share. The Notes were converted into shares of common stock of the Company in accordance with the Conversion Agreement on June 30, 2013.
[F3]Pursuant to the Conversion Agreement, upon conversion of the Notes, the Company agreed to issue a warrant to purchase 75% of the number of shares into which the Notes are convertible.
[F4]Represents shares vested as of February 10, 2014.
[F5]Reflects the expiration of previously reported warrants to purchase 133,334 shares of common stock.

Documents

1 file

4
v368359_4.xmlPrimary
OWNERSHIP DOCUMENT

Issuer

Protea Biosciences Group, Inc.

CIK 0001335103

→

Entity typeoperating

IncorporatedDE

Related Parties

filerCIK 0001335103

Filing Metadata

Form type: 4
Filed: Feb 12, 7:00 PM ET
Accepted: Feb 13, 8:30 PM ET
Size: 23.0 KB

View on SEC.gov